Community Practice Connections™: Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL

Community Practice Connections™: Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory Diffuse large B-cell lymphoma (DLBCL) is organized by Physicians' Education Resource, LLC (PER).

Release Date: January 31, 2020
Expiration Date: January 31, 2021

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Activity Overview:
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and is an aggressive disease. There is a need for continued clinical development of treatment for newly diagnosed and relapsed/refractory (R/R) DLBCL. In the past few years, several novel agents have been approved by the FDA to treat patients with R/R DLBCL, with many more therapies under investigation. The constant emergence of new treatment options is shifting the landscape for clinicians who manage patients with DLBCL. As clinical trials continue to accumulate data, clinicians must consider these results for appropriate patient recruitment into clinical trials and preemptively contemplate how the reported data may change best practice for R/R DLBCL.

This Community Practice Connection™ program will provide an opportunity for clinicians to participate in an online series of video interviews with top experts in DLBCL on current strategies to assess risk, clinical outcomes related to first-line standards of care, exploration of unmet treatment needs for patients with R/R DLBCL, and frontline data pertaining to treatment of transplant-ineligible patients with R/R DLBCL.

Benefits of Participating:
• See how top experts assess risk and manage patients with DLBCL
• Gain expert insights into treatment of transplant-ineligible patients with R/R DLBCL
• Develop strategies to manage therapy-related adverse events
• Learn about emerging agents for patients with R/R DLBCL

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Describe current standards of care and outcomes for patients with DLBCL
• Summarize unmet clinical needs and methods to assess risk in patients with DLBCL
• Explain novel mechanisms of action and therapeutic targets for patients with newly diagnosed or relapsed/refractory DLBCL
• Evaluate the efficacy and adverse event profile of emerging approaches for patients with relapsed/refractory DLBCL